schliessen

Filtern

 

Bibliotheken

Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model

Abstract A DNA plasmid encoding human immunodeficiency virus type 1 (HIV-1) env , nef and tat genes was used in mice in a prime-boost immunization regimen with the corresponding recombinant proteins. The genetic immunogen was delivered with a gene gun and the proteins were injected intramuscularly t... Full description

Journal Title: Vaccine 2006, Vol.25 (11), p.2145-2154
Main Author: Rollman, Erik
Other Authors: Mathy, Nathalie , Bråve, Andreas , Boberg, Andreas , Kjerrström, Anne , van Wely, Cathy , Engström, Gunnel , Johansson, Susanne , Aperia, Kajsa , Eriksson, Lars E , Benthin, Reinhold , Ertl, Peter , Heeney, Jonathan , Hinkula, Jorma , Voss, Gerald , Wahren, Britta
Format: Electronic Article Electronic Article
Language: English
Subjects:
DNA
Env
HIV
Nef
Tat
Quelle: Alma/SFX Local Collection
Publisher: Oxford: Elsevier Ltd
ID: ISSN: 0264-410X
Zum Text:
SendSend as email Add to Book BagAdd to Book Bag
Staff View
recordid: cdi_swepub_primary_oai_prod_swepub_kib_ki_se_12540762
title: Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model
format: Article
creator:
  • Rollman, Erik
  • Mathy, Nathalie
  • Bråve, Andreas
  • Boberg, Andreas
  • Kjerrström, Anne
  • van Wely, Cathy
  • Engström, Gunnel
  • Johansson, Susanne
  • Aperia, Kajsa
  • Eriksson, Lars E
  • Benthin, Reinhold
  • Ertl, Peter
  • Heeney, Jonathan
  • Hinkula, Jorma
  • Voss, Gerald
  • Wahren, Britta
subjects:
  • Adjuvants, Immunologic
  • AIDS Vaccines - immunology
  • Allergy and Immunology
  • Analysis
  • Animals
  • Applied microbiology
  • AS02A
  • Biolistics
  • Biological and medical sciences
  • Cancer
  • Cytokines
  • Deoxyribonucleic acid
  • Disease Models, Animal
  • DNA
  • Drug Combinations
  • Env
  • Fundamental and applied biological sciences. Psychology
  • Genetic aspects
  • HIV
  • HIV (Viruses)
  • HIV Antibodies - blood
  • HIV Antigens - genetics
  • HIV Antigens - immunology
  • HIV Infections - prevention & control
  • HIV-1
  • HIV-1 - immunology
  • HIV/MuLV
  • Human immunodeficiency virus
  • Human immunodeficiency virus 1
  • Human viral diseases
  • Humans
  • Immunization, Secondary
  • Infections
  • Infectious diseases
  • Injections, Intramuscular
  • Leukemia
  • Leukemia Virus, Murine
  • Lipid A - analogs & derivatives
  • Lipid A - immunology
  • Lymphocytes
  • Medical and Health Sciences
  • Medical sciences
  • MEDICIN
  • Medicin och hälsovetenskap
  • MEDICINE
  • Mice
  • Mice, Inbred C57BL
  • Mice, Transgenic
  • Microbiology
  • Miscellaneous
  • Models
  • Murine leukemia virus
  • Nef
  • Peptides
  • Plasmids
  • Prime-boost
  • Proteins
  • Recombinant Proteins - genetics
  • Recombinant Proteins - immunology
  • Retroviridae Infections - prevention & control
  • Saponins - immunology
  • Small animal model
  • T-Lymphocytes - immunology
  • Tat
  • Tumor Virus Infections - prevention & control
  • Vaccination
  • Vaccines
  • Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
  • Vaccines, DNA - immunology
  • Vaccines, Subunit - immunology
  • Viral diseases
  • Viral diseases of the lymphoid tissue and the blood. Aids
  • Virology
  • Virus diseases
ispartof: Vaccine, 2006, Vol.25 (11), p.2145-2154
description: Abstract A DNA plasmid encoding human immunodeficiency virus type 1 (HIV-1) env , nef and tat genes was used in mice in a prime-boost immunization regimen with the corresponding recombinant proteins. The genetic immunogen was delivered with a gene gun and the proteins were injected intramuscularly together with the adjuvant AS02A. Immunizations were followed by experimental challenge with pseudotyped HIV-1 subtype A or B virus. In an initial experiment in which animals were challenged four weeks after the final immunization, all single modality and prime-boost vaccinations resulted in a significant level of protection as compared to control animals. There was a trend for DNA-alone immunization yielding the highest protection. In a subsequent study, a late challenge was performed 19 weeks after the final immunization. All groups having received the DNA vaccine, either alone or in combination with adjuvanted protein, exhibited strong protection against HIV replication. The subtype-specific protection against the experimental HIV challenge was significantly stronger than the cross-protection. Cellular and humoral immune responses were assessed during immunization and after challenge, but without clear correlation to protection against HIV replication. The data suggest that either DNA or protein antigens alone provide partial protection against an HIV-1/MuLV challenge and that DNA immunization is essential for achieving very high levels of efficacy in this murine HIV-1 challenge model. While prime-boost combinations were more immunogenic than DNA alone, they did not appear to provide any further enhancement over DNA vaccine mediated efficacy. The DNA immunogen might prime low levels of CD8+ T cells responsible for virus clearance or possibly a yet unidentified mechanism of protection.
language: eng
source: Alma/SFX Local Collection
identifier: ISSN: 0264-410X
fulltext: fulltext
issn:
  • 0264-410X
  • 1873-2518
  • 1873-2518
url: Link


@attributes
NO1
SEARCH_ENGINEprimo_central_multiple_fe
SEARCH_ENGINE_TYPEPrimo Central Search Engine
RANK2.1376624
LOCALfalse
PrimoNMBib
record
control
sourceidgale_swepu
recordidTN_cdi_swepub_primary_oai_prod_swepub_kib_ki_se_12540762
sourceformatXML
sourcesystemPC
galeidA161174837
sourcerecordidA161174837
originalsourceidFETCH-LOGICAL-c570t-747a609fb6b217620a13563cc0c424eab28aa2d8798c8c45b2022bf8c8b3aba23
addsrcrecordideNqFk9tu1DAQhiMEoqXwCKBICK7Yre0kdvYGtGrLQarggoO4sybOZOttYi9xvGhfjOdjshuxUiXUi8jx-JvfY8_vJHnO2ZwzLs_X8y0YYx3OBWOSYnNWqAfJKS9VNhMFLx8mp0zIfJZz9vMkeRLCmjFWZHzxODnhShS5VOI0-XO1hTbCYL1LfZParovOr9BZY4ddCq5OsWmsAbMbl43vKtqyTi8_L_eLUK_jFtxAoU3vB7QuPZR1UKQppDexAzcp10hiFh3JbW0fQzrsNpjy8y72pJu2GG-xszAtbgLG2u8RcwNti26FaUci7dPkUQNtwGfTeJZ8f3_17eLj7PrLh08Xy-uZKRQbZipXINmiqWQluJKCAc8KmRnDTC5yhEqUAKIu1aI0pcmLSjAhqoYmVQYViOwsKQ-64TduYqU3ve2g32kPlv59raf4rR0_HVBzullGW1Hqm_-mXtofS-37lW5t1JmSeUH46wNOsr8ihkF3NhhsW3DoY9BywbjIC3UvyBcqLwQfC3h5B1z72Du6Ls2LXHFJZsiImh-oFbSorWv80AP1G2pqhPGOGkbxJZecq7zMxv2LQ4LpfQg9Nv9OxpkeranXerKmHq05htm-7hdTObHqsD5mTV4k4NUEQDDQNj04Y8ORK4uSjsWIe3fgkBq_tdjrsLcU1rZHM-ja23tLeXtHwbSWLA_tLe4wHK9JB6GZ_jq-o_EZMck4X0iW_QWSdB2S
sourcetypeOpen Access Repository
isCDItrue
recordtypearticle
pqid1547165313
display
typearticle
titleEvaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model
sourceAlma/SFX Local Collection
creatorRollman, Erik ; Mathy, Nathalie ; Bråve, Andreas ; Boberg, Andreas ; Kjerrström, Anne ; van Wely, Cathy ; Engström, Gunnel ; Johansson, Susanne ; Aperia, Kajsa ; Eriksson, Lars E ; Benthin, Reinhold ; Ertl, Peter ; Heeney, Jonathan ; Hinkula, Jorma ; Voss, Gerald ; Wahren, Britta
creatorcontribRollman, Erik ; Mathy, Nathalie ; Bråve, Andreas ; Boberg, Andreas ; Kjerrström, Anne ; van Wely, Cathy ; Engström, Gunnel ; Johansson, Susanne ; Aperia, Kajsa ; Eriksson, Lars E ; Benthin, Reinhold ; Ertl, Peter ; Heeney, Jonathan ; Hinkula, Jorma ; Voss, Gerald ; Wahren, Britta
descriptionAbstract A DNA plasmid encoding human immunodeficiency virus type 1 (HIV-1) env , nef and tat genes was used in mice in a prime-boost immunization regimen with the corresponding recombinant proteins. The genetic immunogen was delivered with a gene gun and the proteins were injected intramuscularly together with the adjuvant AS02A. Immunizations were followed by experimental challenge with pseudotyped HIV-1 subtype A or B virus. In an initial experiment in which animals were challenged four weeks after the final immunization, all single modality and prime-boost vaccinations resulted in a significant level of protection as compared to control animals. There was a trend for DNA-alone immunization yielding the highest protection. In a subsequent study, a late challenge was performed 19 weeks after the final immunization. All groups having received the DNA vaccine, either alone or in combination with adjuvanted protein, exhibited strong protection against HIV replication. The subtype-specific protection against the experimental HIV challenge was significantly stronger than the cross-protection. Cellular and humoral immune responses were assessed during immunization and after challenge, but without clear correlation to protection against HIV replication. The data suggest that either DNA or protein antigens alone provide partial protection against an HIV-1/MuLV challenge and that DNA immunization is essential for achieving very high levels of efficacy in this murine HIV-1 challenge model. While prime-boost combinations were more immunogenic than DNA alone, they did not appear to provide any further enhancement over DNA vaccine mediated efficacy. The DNA immunogen might prime low levels of CD8+ T cells responsible for virus clearance or possibly a yet unidentified mechanism of protection.
identifier
0ISSN: 0264-410X
1ISSN: 1873-2518
2EISSN: 1873-2518
3DOI: 10.1016/j.vaccine.2006.10.057
4PMID: 17254672
5CODEN: VACCDE
languageeng
publisherOxford: Elsevier Ltd
subjectAdjuvants, Immunologic ; AIDS Vaccines - immunology ; Allergy and Immunology ; Analysis ; Animals ; Applied microbiology ; AS02A ; Biolistics ; Biological and medical sciences ; Cancer ; Cytokines ; Deoxyribonucleic acid ; Disease Models, Animal ; DNA ; Drug Combinations ; Env ; Fundamental and applied biological sciences. Psychology ; Genetic aspects ; HIV ; HIV (Viruses) ; HIV Antibodies - blood ; HIV Antigens - genetics ; HIV Antigens - immunology ; HIV Infections - prevention & control ; HIV-1 ; HIV-1 - immunology ; HIV/MuLV ; Human immunodeficiency virus ; Human immunodeficiency virus 1 ; Human viral diseases ; Humans ; Immunization, Secondary ; Infections ; Infectious diseases ; Injections, Intramuscular ; Leukemia ; Leukemia Virus, Murine ; Lipid A - analogs & derivatives ; Lipid A - immunology ; Lymphocytes ; Medical and Health Sciences ; Medical sciences ; MEDICIN ; Medicin och hälsovetenskap ; MEDICINE ; Mice ; Mice, Inbred C57BL ; Mice, Transgenic ; Microbiology ; Miscellaneous ; Models ; Murine leukemia virus ; Nef ; Peptides ; Plasmids ; Prime-boost ; Proteins ; Recombinant Proteins - genetics ; Recombinant Proteins - immunology ; Retroviridae Infections - prevention & control ; Saponins - immunology ; Small animal model ; T-Lymphocytes - immunology ; Tat ; Tumor Virus Infections - prevention & control ; Vaccination ; Vaccines ; Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects) ; Vaccines, DNA - immunology ; Vaccines, Subunit - immunology ; Viral diseases ; Viral diseases of the lymphoid tissue and the blood. Aids ; Virology ; Virus diseases
ispartofVaccine, 2006, Vol.25 (11), p.2145-2154
rights
0Elsevier Ltd
12006 Elsevier Ltd
22007 INIST-CNRS
3COPYRIGHT 2007 Elsevier B.V.
4Copyright Elsevier Limited Mar 1, 2007
lds50peer_reviewed
links
openurl$$Topenurl_article
openurlfulltext$$Topenurlfull_article
thumbnail$$Usyndetics_thumb_exl
backlink
0$$Uhttp://pascal-francis.inist.fr/vibad/index.php?action=getRecordDetail&idt=18582120$$DView record in Pascal Francis
1$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/17254672$$D View this record in MEDLINE/PubMed
2$$Uhttp://urn.kb.se/resolve?urn=urn:nbn:se:liu:diva-37645$$DView record from Swedish Publication Index
3$$Uhttp://kipublications.ki.se/Default.aspx?queryparsed=id:12540762$$DView record from Swedish Publication Index
search
creatorcontrib
0Rollman, Erik
1Mathy, Nathalie
2Bråve, Andreas
3Boberg, Andreas
4Kjerrström, Anne
5van Wely, Cathy
6Engström, Gunnel
7Johansson, Susanne
8Aperia, Kajsa
9Eriksson, Lars E
10Benthin, Reinhold
11Ertl, Peter
12Heeney, Jonathan
13Hinkula, Jorma
14Voss, Gerald
15Wahren, Britta
title
0Evaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model
1Vaccine
addtitleVaccine
descriptionAbstract A DNA plasmid encoding human immunodeficiency virus type 1 (HIV-1) env , nef and tat genes was used in mice in a prime-boost immunization regimen with the corresponding recombinant proteins. The genetic immunogen was delivered with a gene gun and the proteins were injected intramuscularly together with the adjuvant AS02A. Immunizations were followed by experimental challenge with pseudotyped HIV-1 subtype A or B virus. In an initial experiment in which animals were challenged four weeks after the final immunization, all single modality and prime-boost vaccinations resulted in a significant level of protection as compared to control animals. There was a trend for DNA-alone immunization yielding the highest protection. In a subsequent study, a late challenge was performed 19 weeks after the final immunization. All groups having received the DNA vaccine, either alone or in combination with adjuvanted protein, exhibited strong protection against HIV replication. The subtype-specific protection against the experimental HIV challenge was significantly stronger than the cross-protection. Cellular and humoral immune responses were assessed during immunization and after challenge, but without clear correlation to protection against HIV replication. The data suggest that either DNA or protein antigens alone provide partial protection against an HIV-1/MuLV challenge and that DNA immunization is essential for achieving very high levels of efficacy in this murine HIV-1 challenge model. While prime-boost combinations were more immunogenic than DNA alone, they did not appear to provide any further enhancement over DNA vaccine mediated efficacy. The DNA immunogen might prime low levels of CD8+ T cells responsible for virus clearance or possibly a yet unidentified mechanism of protection.
subject
0Adjuvants, Immunologic
1AIDS Vaccines - immunology
2Allergy and Immunology
3Analysis
4Animals
5Applied microbiology
6AS02A
7Biolistics
8Biological and medical sciences
9Cancer
10Cytokines
11Deoxyribonucleic acid
12Disease Models, Animal
13DNA
14Drug Combinations
15Env
16Fundamental and applied biological sciences. Psychology
17Genetic aspects
18HIV
19HIV (Viruses)
20HIV Antibodies - blood
21HIV Antigens - genetics
22HIV Antigens - immunology
23HIV Infections - prevention & control
24HIV-1
25HIV-1 - immunology
26HIV/MuLV
27Human immunodeficiency virus
28Human immunodeficiency virus 1
29Human viral diseases
30Humans
31Immunization, Secondary
32Infections
33Infectious diseases
34Injections, Intramuscular
35Leukemia
36Leukemia Virus, Murine
37Lipid A - analogs & derivatives
38Lipid A - immunology
39Lymphocytes
40Medical and Health Sciences
41Medical sciences
42MEDICIN
43Medicin och hälsovetenskap
44MEDICINE
45Mice
46Mice, Inbred C57BL
47Mice, Transgenic
48Microbiology
49Miscellaneous
50Models
51Murine leukemia virus
52Nef
53Peptides
54Plasmids
55Prime-boost
56Proteins
57Recombinant Proteins - genetics
58Recombinant Proteins - immunology
59Retroviridae Infections - prevention & control
60Saponins - immunology
61Small animal model
62T-Lymphocytes - immunology
63Tat
64Tumor Virus Infections - prevention & control
65Vaccination
66Vaccines
67Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
68Vaccines, DNA - immunology
69Vaccines, Subunit - immunology
70Viral diseases
71Viral diseases of the lymphoid tissue and the blood. Aids
72Virology
73Virus diseases
issn
00264-410X
11873-2518
21873-2518
fulltexttrue
rsrctypearticle
creationdate2006
recordtypearticle
recordideNqFk9tu1DAQhiMEoqXwCKBICK7Yre0kdvYGtGrLQarggoO4sybOZOttYi9xvGhfjOdjshuxUiXUi8jx-JvfY8_vJHnO2ZwzLs_X8y0YYx3OBWOSYnNWqAfJKS9VNhMFLx8mp0zIfJZz9vMkeRLCmjFWZHzxODnhShS5VOI0-XO1hTbCYL1LfZParovOr9BZY4ddCq5OsWmsAbMbl43vKtqyTi8_L_eLUK_jFtxAoU3vB7QuPZR1UKQppDexAzcp10hiFh3JbW0fQzrsNpjy8y72pJu2GG-xszAtbgLG2u8RcwNti26FaUci7dPkUQNtwGfTeJZ8f3_17eLj7PrLh08Xy-uZKRQbZipXINmiqWQluJKCAc8KmRnDTC5yhEqUAKIu1aI0pcmLSjAhqoYmVQYViOwsKQ-64TduYqU3ve2g32kPlv59raf4rR0_HVBzullGW1Hqm_-mXtofS-37lW5t1JmSeUH46wNOsr8ihkF3NhhsW3DoY9BywbjIC3UvyBcqLwQfC3h5B1z72Du6Ls2LXHFJZsiImh-oFbSorWv80AP1G2pqhPGOGkbxJZecq7zMxv2LQ4LpfQg9Nv9OxpkeranXerKmHq05htm-7hdTObHqsD5mTV4k4NUEQDDQNj04Y8ORK4uSjsWIe3fgkBq_tdjrsLcU1rZHM-ja23tLeXtHwbSWLA_tLe4wHK9JB6GZ_jq-o_EZMck4X0iW_QWSdB2S
startdate2006
enddate2006
creator
0Rollman, Erik
1Mathy, Nathalie
2Bråve, Andreas
3Boberg, Andreas
4Kjerrström, Anne
5van Wely, Cathy
6Engström, Gunnel
7Johansson, Susanne
8Aperia, Kajsa
9Eriksson, Lars E
10Benthin, Reinhold
11Ertl, Peter
12Heeney, Jonathan
13Hinkula, Jorma
14Voss, Gerald
15Wahren, Britta
general
0Elsevier Ltd
1Elsevier
2Elsevier B.V
3Elsevier Limited
scope
0IQODW
1CGR
2CUY
3CVF
4ECM
5EIF
6NPM
7AAYXX
8CITATION
9BSHEE
103V.
117QL
127RV
137T2
147T5
157U9
167X7
177XB
1888C
1988E
208AO
218C1
228FE
238FH
248FI
258FJ
268FK
278G5
28ABUWG
29AZQEC
30BBNVY
31BENPR
32BHPHI
33C1K
34DWQXO
35FYUFA
36GHDGH
37GNUQQ
38GUQSH
39H94
40HCIFZ
41K9-
42K9.
43KB0
44LK8
45M0R
46M0S
47M0T
48M1P
49M2O
50M7N
51M7P
52MBDVC
53NAPCQ
54PQEST
55PQQKQ
56PQUKI
57Q9U
587QO
597TM
608FD
61FR3
62P64
637X8
64ADTPV
65AOWAS
sort
creationdate2006
titleEvaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model
authorRollman, Erik ; Mathy, Nathalie ; Bråve, Andreas ; Boberg, Andreas ; Kjerrström, Anne ; van Wely, Cathy ; Engström, Gunnel ; Johansson, Susanne ; Aperia, Kajsa ; Eriksson, Lars E ; Benthin, Reinhold ; Ertl, Peter ; Heeney, Jonathan ; Hinkula, Jorma ; Voss, Gerald ; Wahren, Britta
facets
frbrtype5
frbrgroupidcdi_FETCH-LOGICAL-c570t-747a609fb6b217620a13563cc0c424eab28aa2d8798c8c45b2022bf8c8b3aba23
rsrctypearticles
prefilterarticles
languageeng
creationdate2006
topic
0Adjuvants, Immunologic
1AIDS Vaccines - immunology
2Allergy and Immunology
3Analysis
4Animals
5Applied microbiology
6AS02A
7Biolistics
8Biological and medical sciences
9Cancer
10Cytokines
11Deoxyribonucleic acid
12Disease Models, Animal
13DNA
14Drug Combinations
15Env
16Fundamental and applied biological sciences. Psychology
17Genetic aspects
18HIV
19HIV (Viruses)
20HIV Antibodies - blood
21HIV Antigens - genetics
22HIV Antigens - immunology
23HIV Infections - prevention & control
24HIV-1
25HIV-1 - immunology
26HIV/MuLV
27Human immunodeficiency virus
28Human immunodeficiency virus 1
29Human viral diseases
30Humans
31Immunization, Secondary
32Infections
33Infectious diseases
34Injections, Intramuscular
35Leukemia
36Leukemia Virus, Murine
37Lipid A - analogs & derivatives
38Lipid A - immunology
39Lymphocytes
40Medical and Health Sciences
41Medical sciences
42MEDICIN
43Medicin och hälsovetenskap
44MEDICINE
45Mice
46Mice, Inbred C57BL
47Mice, Transgenic
48Microbiology
49Miscellaneous
50Models
51Murine leukemia virus
52Nef
53Peptides
54Plasmids
55Prime-boost
56Proteins
57Recombinant Proteins - genetics
58Recombinant Proteins - immunology
59Retroviridae Infections - prevention & control
60Saponins - immunology
61Small animal model
62T-Lymphocytes - immunology
63Tat
64Tumor Virus Infections - prevention & control
65Vaccination
66Vaccines
67Vaccines, antisera, therapeutical immunoglobulins and monoclonal antibodies (general aspects)
68Vaccines, DNA - immunology
69Vaccines, Subunit - immunology
70Viral diseases
71Viral diseases of the lymphoid tissue and the blood. Aids
72Virology
73Virus diseases
toplevel
0peer_reviewed
1online_resources
creatorcontrib
0Rollman, Erik
1Mathy, Nathalie
2Bråve, Andreas
3Boberg, Andreas
4Kjerrström, Anne
5van Wely, Cathy
6Engström, Gunnel
7Johansson, Susanne
8Aperia, Kajsa
9Eriksson, Lars E
10Benthin, Reinhold
11Ertl, Peter
12Heeney, Jonathan
13Hinkula, Jorma
14Voss, Gerald
15Wahren, Britta
collection
0Pascal-Francis
1Medline
2MEDLINE
3MEDLINE (Ovid)
4MEDLINE
5MEDLINE
6PubMed
7CrossRef
8Academic OneFile (A&I only)
9ProQuest Central (Corporate)
10Bacteriology Abstracts (Microbiology B)
11Nursing & Allied Health Database
12Health and Safety Science Abstracts (Full archive)
13Immunology Abstracts
14Virology and AIDS Abstracts
15Health & Medical Collection
16ProQuest Central (purchase pre-March 2016)
17Healthcare Administration Database (Alumni)
18Medical Database (Alumni Edition)
19ProQuest Pharma Collection
20Public Health Database
21ProQuest SciTech Collection
22ProQuest Natural Science Collection
23Hospital Premium Collection
24Hospital Premium Collection (Alumni Edition)
25ProQuest Central (Alumni) (purchase pre-March 2016)
26Research Library (Alumni Edition)
27ProQuest Central (Alumni Edition)
28ProQuest Central Essentials
29Biological Science Collection
30ProQuest Central
31Natural Science Collection
32Environmental Sciences and Pollution Management
33ProQuest Central Korea
34Health Research Premium Collection
35Health Research Premium Collection (Alumni)
36ProQuest Central Student
37Research Library Prep
38AIDS and Cancer Research Abstracts
39SciTech Premium Collection
40Consumer Health Database (Alumni Edition)
41ProQuest Health & Medical Complete (Alumni)
42Nursing & Allied Health Database (Alumni Edition)
43ProQuest Biological Science Collection
44Consumer Health Database
45Health & Medical Collection (Alumni Edition)
46Healthcare Administration Database
47Medical Database
48Research Library
49Algology Mycology and Protozoology Abstracts (Microbiology C)
50Biological Science Database
51Research Library (Corporate)
52Nursing & Allied Health Premium
53ProQuest One Academic Eastern Edition
54ProQuest One Academic
55ProQuest One Academic UKI Edition
56ProQuest Central Basic
57Biotechnology Research Abstracts
58Nucleic Acids Abstracts
59Technology Research Database
60Engineering Research Database
61Biotechnology and BioEngineering Abstracts
62MEDLINE - Academic
63SwePub
64SwePub Articles
jtitleVaccine
delivery
delcategoryRemote Search Resource
fulltextfulltext
addata
au
0Rollman, Erik
1Mathy, Nathalie
2Bråve, Andreas
3Boberg, Andreas
4Kjerrström, Anne
5van Wely, Cathy
6Engström, Gunnel
7Johansson, Susanne
8Aperia, Kajsa
9Eriksson, Lars E
10Benthin, Reinhold
11Ertl, Peter
12Heeney, Jonathan
13Hinkula, Jorma
14Voss, Gerald
15Wahren, Britta
formatjournal
genrearticle
ristypeJOUR
atitleEvaluation of immunogenicity and efficacy of combined DNA and adjuvanted protein vaccination in a human immunodeficiency virus type 1/murine leukemia virus pseudotype challenge model
jtitleVaccine
addtitleVaccine
date2006
risdate2006
volume25
issue11
spage2145
epage2154
pages2145-2154
issn
00264-410X
11873-2518
eissn1873-2518
codenVACCDE
abstractAbstract A DNA plasmid encoding human immunodeficiency virus type 1 (HIV-1) env , nef and tat genes was used in mice in a prime-boost immunization regimen with the corresponding recombinant proteins. The genetic immunogen was delivered with a gene gun and the proteins were injected intramuscularly together with the adjuvant AS02A. Immunizations were followed by experimental challenge with pseudotyped HIV-1 subtype A or B virus. In an initial experiment in which animals were challenged four weeks after the final immunization, all single modality and prime-boost vaccinations resulted in a significant level of protection as compared to control animals. There was a trend for DNA-alone immunization yielding the highest protection. In a subsequent study, a late challenge was performed 19 weeks after the final immunization. All groups having received the DNA vaccine, either alone or in combination with adjuvanted protein, exhibited strong protection against HIV replication. The subtype-specific protection against the experimental HIV challenge was significantly stronger than the cross-protection. Cellular and humoral immune responses were assessed during immunization and after challenge, but without clear correlation to protection against HIV replication. The data suggest that either DNA or protein antigens alone provide partial protection against an HIV-1/MuLV challenge and that DNA immunization is essential for achieving very high levels of efficacy in this murine HIV-1 challenge model. While prime-boost combinations were more immunogenic than DNA alone, they did not appear to provide any further enhancement over DNA vaccine mediated efficacy. The DNA immunogen might prime low levels of CD8+ T cells responsible for virus clearance or possibly a yet unidentified mechanism of protection.
copOxford
pubElsevier Ltd
pmid17254672
doi10.1016/j.vaccine.2006.10.057